Beta-blockers in refractory ascites – is it truly the end of the road?

We read with great interest the study by Tellez et  al.1 highlighting mechanisms of hemodynamic alterations and associated renal dysfunction with the use of a 4-week non-selective beta-blocker (NSBB) therapy in refractory ascites (RA) and diuretic responsive ascites (DRA).1 They proposed ejection intra-ventricular pressure difference (EIVPD) as a n ovel load-independent measure that predicts LV systolic function decline better than standard load-dependent measures (ejection fraction and stroke volume).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research